biostudies-literatureNg CShanghai Municipal Health CommissionScience and Technology Commission of Shanghai MunicipalityWu Jieping Medical FoundationBeijing Xisike Clinical Oncology Research FoundationNational Natural Science Foundation of China304https://www.ebi.ac.uk/biostudies/studies/S-EPMC12433416biostudies-literatureUnknown74(10)<h4>Background</h4>Disitamab vedotin (DV, RC48-ADC) has shown promising efficacy and manageable safety as monotherapy or combined with immune checkpoint inhibitors (ICIs) in metastatic urothelial carcinoma (mUC) patients progressing after systemic chemotherapy. This study evaluates the efficacy and safety of RC48-ADC plus ICIs in metastatic upper tract urothelial carcinoma (mUTUC) in a real-world setting.<h4>Methods</h4>This retrospective, multicenter study included 198 mUTUC patients treated with RC48-ADC plus ICI at 23 clinical centers between June 2021 and December 2023. Data were analyzed from July to September 2024.<h4>Primary endpoint</h4>objective response rate (ORR). Secondary endpoints: progression-free survival (PFS), overall survival (OS), duration of response (DoR), time to objCancer immunology, immunotherapy : CIIThe efficacy and safety of disitamab vedotin combined with immune checkpoint inhibitors in metastatic upper tract urothelial carcinoma: a multicenter real-world study.PMC1243341682102748Y-Gilead2024-PT-005424ZR14920002023ZZ02014320.6750.2022-19-92Wu JDing GYu SHuang JHu XWei XZhang SJing TShen HXiong WBi HXue WLiu ZYan ZTang QNg CXia DJia ZYuan YChen MBao YZhang THuang ZHuang WXiao JHu HYang QYe JfalseThe efficacy and safety of disitamab vedotin combined with immune checkpoint inhibitors in metastatic upper tract urothelial carcinoma: a multicenter real-world study.<h4>Background</h4>Disitamab vedotin (DV, RC48-ADC) has shown promising efficacy and manageable safety as monotherapy or combined with immune checkpoint inhibitors (ICIs) in metastatic urothelial carcinoma (mUC) patients progressing after systemic chemotherapy. This study evaluates the efficacy and safety of RC48-ADC plus ICIs in metastatic upper tract urothelial carcinoma (mUTUC) in a real-world setting.<h4>Methods</h4>This retrospective, multicenter study included 198 mUTUC patients treated with RC48-ADC plus ICI at 23 clinical centers between June 2021 and December 2023. Data were analyzed from July to September 2024.<h4>Primary endpoint</h4>objective response rate (ORR). Secondary endpoints: progression-free survival (PFS), overall survival (OS), duration of response (DoR), time to obj2025-01-01T00:00:00Z2025 Sep2026-06-01T06:34:54.388Z2026-04-08T10:05:12.527ZS-EPMC124334164094472710.1007/s00262-025-04154-5